Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively defined, there is evidence that pregabalin exerts its effects by bind...
Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.
Pinnacle Research Group, LLC, Anniston, Alabama, United States
Synexus Clinical Research US - Birmingham, Birmingham, Alabama, United States
Synexus Clinical Research US - Phoenix Central, Phoenix, Arizona, United States
AMR Fort Myers (The Clinical Study Center), Fort Myers, Florida, United States
Innovation Medical Research Center, Palmetto Bay, Florida, United States
ARSN - NeuroStudies, Decatur, Georgia, United States
Beth Israel Deaconess Medical Center for Autonomic and Peripheral Nerve Disorders, Boston, Massachusetts, United States
Washington University School of Medicine, St. Louis, Missouri, United States
University of Rochester, Rochester, New York, United States
Sichuan Provincial People's Hospita, Chengdu, Sichuan, China
Xiaoyu Li, Hangzhou, Zhejiang, China
Thammasat University Hospital, Khlong Luang, Pathum Thani, Thailand
Peking University First Hospital, Beijing, Beijing, China
Helsinki University Hospital, Department of Neurology, Helsinki, Uusimaa, Finland
Helsinki University Central Hospital, Helsinki, HUS, Finland
Centre for Human Drug Research, Leiden, Netherlands
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.